AURA - Aura Biosciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

12.66

-0.17

(-1.33%)

At close: 04:00PM EDT

12.66

0.00

(0.00%)

After hours:

04:01PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Relative Strength Index (RSI)

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	12.83
Open	12.82
Bid	12.10 x 1100
Ask	13.50 x 900
Day's Range	12.60 - 13.02
52 Week Range	8.13 - 24.83
Volume	43,854
Avg. Volume	105,009

Market Cap	497.199M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-2.08
Earnings Date	May 11, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	30.67

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AURA

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 24, 2023--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
Business Wire
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
BOSTON, May 12, 2023--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023, at 2:00 p.m. ET.
Business Wire
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON, May 11, 2023--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2023, and provided clinical development and operational highlights.
Simply Wall St.
Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year
Viewing insider transactions for Aura Biosciences, Inc.'s ( NASDAQ:AURA ) over the last year, we see that insiders were...
Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON, March 15, 2023--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights.
Simply Wall St.
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Benzinga
Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate
Aura Biosciences Inc (NASDAQ: AURA) announced the presentation of interim Phase 2 safety and efficacy data of belzupacap sarotalocan (bel-sar; AU-011) with 9-10 months of follow-up. The trial evaluates two clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal (SC) route of administration for early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (IL/CM)). The results showed a statistically significant reduction in the tumor growth r
Business Wire
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
BOSTON, February 16, 2023--Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of positive interim Phase 2 safety and efficacy data of bel-sar with 9-10 months of follow up evaluating two key clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal (SC) route of administration for the first-li
Motley Fool
Why Shares of Aura Biosciences Jumped This Week
The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.
Simply Wall St.
Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year losses
A look at the shareholders of Aura Biosciences, Inc. ( NASDAQ:AURA ) can tell us which group is most powerful. And the...
Insider Monkey
12 Stocks Insiders are Buying Now
In this article, we will look at the 12 stocks insiders are buying now. If you want to explore similar stocks, you can also take a look at 5 Stocks Insiders are Buying Now. Investing in stocks that insiders are buying can sometimes lead to unexpected gains. Insiders, such as company executives, board members, and major […]
Business Wire
Aura Biosciences Announces Pricing of Public Offering of Common Stock
BOSTON, December 01, 2022--Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a price to the public of $12.00 per share. The gross proceeds from the offering to Aura are expected to be $80.4 million, before deducting underwriting discounts and commissio
Business Wire
Aura Biosciences Announces Proposed Public Offering of Common Stock
BOSTON, November 30, 2022--Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Aura. Aura also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its co
Business Wire
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON, November 10, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights.
Business Wire
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
BOSTON, November 10, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that it has initiated startup activities for the global Phase 3 trial. After presenting positive interim data at the American Academy of Ophthalmology from its ongoing Phase 2 trial, Aura has aligned with regulatory agencies and finalized the design of the global Phase 3 tri
Simply Wall St.
Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswire
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
- Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS®) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector® - - SCS Microinjector® Featured in Multiple Oral and Poster Presentations at Recent American Academy of Ophthalmology (AAO) 2022 Annual Meeting - ALPHARETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies
Benzinga
Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug
Aura Biosciences Inc (NASDAQ: AURA) detailed interim data from its ongoing Phase 2 trial of an eye cancer drug, elzupacap sarotalocan (AU‑011). Belzupacap sarotalocan controlled tumors in most patients on longer treatment cycles. Nearly all patients retained their vision in an interim look at the Phase 2 trial, with a data cutoff of Aug. 19, at the American Academy of Ophthalmology conference in the Second City. Two of the nine patients received 40 μg, and the other seven were given 80 μg. Accor
Business Wire
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
BOSTON, October 03, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that interim Phase 2 data evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU‑011), for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and s
Business Wire
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
BOSTON, September 28, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’s first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
Business Wire
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
BOSTON, September 27, 2022--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indetermi
Business Wire
Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress
CAMBRIDGE, Mass., September 07, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Phase 2 data evaluating the safety of suprachoroidal administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal
Business Wire
Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
CAMBRIDGE, Mass., September 01, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indeterminate lesions and small choroidal melanoma (IL/CM)]. The presentations include
Business Wire
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON, August 11, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2022, and provided clinical development and operational highlights.
Business Wire
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
CAMBRIDGE, Mass., August 02, 2022--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, and Julie Feder, Chief Financial Officer, of Aura will participate in a fireside chat at the 2022 Hybrid BTIG Biotechnology Conference on Monday, August 8, 2022, at 9:00 a.m. ET.